An Open Retrospective Study of a Standardized Cannabidiol Based- Oil in Treatment- Resistant Epilepsy

Epilepsy is one of the most common chronic disorders of the brain affecting around 70 million people worldwide. Treatment is mainly symptomatic, and most individuals have a favorable prognosis and achieve long-term seizure control.1 However, almost one-third of the patients’ results show resistance to anticonvulsant therapy. Pharmacoresistance is defined by the failure to reach a complete or acceptable control in response to antiepileptic drugs.2,3 Despite the increasing number of available treatments, including drugs, neuromodulation, and surgical and dietary interventions, the burden of treatment-resistant epilepsy (TRE) has remained stable over the years, and the search for alternative and adjunctive therapies is likely to be of great interest.4,5